Investigational Drug Information for L-Leucine
✉ Email this page to a colleague
What is the development status for investigational drug L-Leucine?
L-Leucine is an investigational drug.
There have been 30 clinical trials for L-Leucine.
The most recent clinical trial was a Phase 3 trial, which was initiated on October 18th 2001.
The most common disease conditions in clinical trials are Neuroblastoma, Ganglioneuroblastoma, and Breast Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), Roswell Park Cancer Institute, and IntraBio Inc.
Summary for L-Leucine
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 4,226 |
| WIPO Patent Applications | 2,926 |
| Japanese Patent Applications | 16 |
| Clinical Trial Progress | Phase 3 (2001-10-18) |
| Vendors | 95 |
Recent Clinical Trials for L-Leucine
| Title | Sponsor | Phase |
|---|---|---|
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study | National Cancer Institute (NCI) | Phase 1 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study | Mayo Clinic | Phase 1 |
| A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C | IntraBio Inc | Phase 3 |
Clinical Trial Summary for L-Leucine
Top disease conditions for L-Leucine
Top clinical trial sponsors for L-Leucine
US Patents for L-Leucine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
